Serious adverse events: No serious adverse events have been reported in the published research on either BPC-157 or TB-500 at therapeutic doses
Expanding GLP-1 Indications Beyond Obesity and Diabetes While obesity and type 2 diabetes remain the primary targets for GLP-1 drugs, there is growing interest in expanding the use of these drugs to treat other metabolic and cardiovascular conditions
"The way our community and our society looks starts with our home situation, so I'm super glad that there's a change and some momentum into what fatherhood can or should look like," he says
533,537,538,539 In particularly, within macrophages, two lines of host defense are observed: zinc sequestration and zinc intoxication
However, it also has been shown to cause hepatocellular injury